Loading...
Market
What will be the visual acuity preservation rate in the Phase 3 trial of Bel-sar by December 31, 2025?
2
Resolution / Starting Odds
Below 80% • 25%
80% to 85% • 25%
85% to 90% • 25%
Above 90% • 25%
ClinicalTrials.gov and Aura Biosciences press releases
Story
Aura Biosciences Reports Positive Phase 2 Results for Bel-sar in Choroidal Melanoma, 80% Tumor Control Rate
Sep 12, 2024, 11:50 AM
Aura Biosciences has announced positive Phase 2 end-of-study results for its drug Bel-sar, which is being evaluated as a first-line treatment for early-stage choroidal melanoma. The study demonstrated an 80% tumor control rate and a 90% visual acuity preservation rate, with a highly favorable safety profile. These promising results have led to a 7.5% increase in Aura Biosciences' stock price pre-market.
View original story
Similar markets
0-10 patients • 25%
11-20 patients • 25%
21-30 patients • 25%
More than 30 patients • 25%
0-25% • 25%
26-50% • 25%
51-75% • 25%
76-100% • 25%
Less than 30% • 25%
30% to 49% • 25%
50% to 69% • 25%
70% or higher • 25%
0-5 patients • 25%
6-10 patients • 25%
11-15 patients • 25%
More than 15 patients • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 50% efficacy • 25%
50-69% efficacy • 25%
70-89% efficacy • 25%
90% or higher efficacy • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Positive results for B-cell malignancies • 25%
Positive results for autoimmune diseases • 25%
Negative results for both • 25%
Mixed results • 25%
Yes • 50%
No • 50%
Significantly better • 25%
Moderately better • 25%
Similar • 25%
Worse • 25%
Successful with no major adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Unsuccessful due to major adverse effects • 25%